Scroll for more




John H. Johnson
Lead Independent Director, Board of Directors


Mr. Johnson became our Lead Independent Director in January 2016 and has been a Director of Sucampo since December 2014. He most recently served as the President and Chief Executive Officer of Dendreon Corporation, a biotechnology company focused on cancer, from 2012 to July 2014. Prior to Dendreon, Mr. Johnson served as the Chief Executive Officer of Savient Pharmaceuticals, Inc., from 2011 to 2012, and as President of Eli Lilly & Company’s Oncology Unit following its 2008 acquisition of Imclone Systems, Inc. He previously held executive roles of increasing responsibility at Johnson & Johnson, where he worked from 1988 to 2007.

Mr. Johnson is currently the Chairman of the Board of Directors of Cortendo AB, a global biopharmaceutical company focused on orphan endocrine disorders. He also serves as a member of the Board of Directors of Cempra Inc., a clinical-stage pharmaceutical company, Portola Pharmaceuticals, Inc., a biopharmaceutical company, and Histogenics Corporation, a regenerative medicine company. Previously, he served as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

Mr. Johnson earned a bachelor’s degree from East Stroudsburg University of Pennsylvania.

Contact Us
Tel: +1-301-961-3400